TEDxYouth@ISASKinkaid – Camiel Duytschaever

12-12-2011 11:02 Camiel Duytschaver Camiel is concerned about fossil fuel dependency. Camiel first became interested in biofuel while working with energy concepts. Now, she and her partner, Lou Posada, plan to propose a program that would allow schools to use their own resources for energy. Outside the science lab, Camiel also enjoys working in the photography lab, where she blends a passion for both science and art. Lou Posada Lou has had an interest in science for as long as he can remember. Lou is particularly interested in working with nano-medicine, a new form of medicine using nanoparticles. Today, Lou will be talking about biodiesel; more specifically, Lou and his classmate will be discussing a program for promoting the use of biofuel in schools, local communities, nationally, and perhaps worldwide as well. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)

Visit link:
TEDxYouth@ISASKinkaid - Camiel Duytschaever

Nanotube technology leading to new era of fast, lower-cost medical diagnostics

ScienceDaily (Mar. 9, 2012) Researchers at Oregon State University have tapped into the extraordinary power of carbon "nanotubes" to increase the speed of biological sensors, a technology that might one day allow a doctor to routinely perform lab tests in minutes, speeding diagnosis and treatment while reducing costs.

The new findings have almost tripled the speed of prototype nano-biosensors, and should find applications not only in medicine but in toxicology, environmental monitoring, new drug development and other fields.

The research was just reported in Lab on a Chip, a professional journal. More refinements are necessary before the systems are ready for commercial production, scientists say, but they hold great potential.

"With these types of sensors, it should be possible to do many medical lab tests in minutes, allowing the doctor to make a diagnosis during a single office visit," said Ethan Minot, an OSU assistant professor of physics. "Many existing tests take days, cost quite a bit and require trained laboratory technicians.

"This approach should accomplish the same thing with a hand-held sensor, and might cut the cost of an existing $50 lab test to about $1," he said.

The key to the new technology, the researchers say, is the unusual capability of carbon nanotubes. An outgrowth of nanotechnology, which deals with extraordinarily small particles near the molecular level, these nanotubes are long, hollow structures that have unique mechanical, optical and electronic properties, and are finding many applications.

In this case, carbon nanotubes can be used to detect a protein on the surface of a sensor. The nanotubes change their electrical resistance when a protein lands on them, and the extent of this change can be measured to determine the presence of a particular protein -- such as serum and ductal protein biomarkers that may be indicators of breast cancer.

The newest advance was the creation of a way to keep proteins from sticking to other surfaces, like fluid sticking to the wall of a pipe. By finding a way to essentially "grease the pipe," OSU researchers were able to speed the sensing process by 2.5 times.

Further work is needed to improve the selective binding of proteins, the scientists said, before it is ready to develop into commercial biosensors.

"Electronic detection of blood-borne biomarker proteins offers the exciting possibility of point-of-care medical diagnostics," the researchers wrote in their study. "Ideally such electronic biosensor devices would be low-cost and would quantify multiple biomarkers within a few minutes."

Read more:
Nanotube technology leading to new era of fast, lower-cost medical diagnostics

3-D Printer with Nano-Precision

ScienceDaily (Mar. 12, 2012) Printing three-dimensional objects with incredibly fine details is now possible using "two-photon lithography." With this technology, tiny structures on a nanometer scale can be fabricated. Researchers at the Vienna University of Technology (TU Vienna) have now made a major breakthrough in speeding up this printing technique: The high-precision-3D-printer at TU Vienna is orders of magnitude faster than similar devices. This opens up completely new areas of application, such as in medicine.

Setting a New World Record

The 3D printer uses a liquid resin, which is hardened at precisely the correct spots by a focused laser beam. The focal point of the laser beam is guided through the resin by movable mirrors and leaves behind a hardened line of solid polymer, just a few hundred nanometers wide. This fine resolution enables the creation of intricately structured sculptures as tiny as a grain of sand. "Until now, this technique used to be quite slow," says Professor Jrgen Stampfl from the Institute of Materials Science and Technology at the TU Vienna. "The printing speed used to be measured in millimeters per second -- our device can do five meters in one second." In two-photon lithography, this is a world record.

This amazing progress was made possible by combining several new ideas. "It was crucial to improve the steering mechanism of the mirrors," says Jan Torgersen (TU Vienna). The mirrors are continuously in motion during the printing process. The acceleration and deceleration-periods have to be tuned very precisely to achieve high-resolution results at a record-breaking speed.

Photoactive Molecules Harden the Resin

3D-printing is not all about mechanics -- chemists had a crucial role to play in this project too. "The resin contains molecules, which are activated by the laser light. They induce a chain reaction in other components of the resin, so-called monomers, and turn them into a solid," says Jan Torgersen. These initiator molecules are only activated if they absorb two photons of the laser beam at once -- and this only happens in the very center of the laser beam, where the intensity is highest. In contrast to conventional 3D-printing techniques, solid material can be created anywhere within the liquid resin rather than on top of the previously created layer only. Therefore, the working surface does not have to be specially prepared before the next layer can be produced, which saves a lot of time. A team of chemists led by Professor Robert Liska (TU Vienna) developed the suitable ingredients for this special resin.

Researchers all over the world are working on 3D printers today -- at universities as well as in industry. Because of the dramatically increased speed, much larger objects can now be created in a given period of time. This makes two-photon-lithography an interesting technique for industry.

At the TU Vienna, scientists are now developing bio-compatible resins for medical applications. They can be used to create scaffolds to which living cells can attach themselves facilitating the systematic creation of biological tissues. The 3d printer could also be used to create tailor made construction parts for biomedical technology or nanotechnology.

Video: http://amt.tuwien.ac.at/fileadmin/t/amt/research/High_Speed_2PP.mpg

Share this story on Facebook, Twitter, and Google:

Here is the original post:
3-D Printer with Nano-Precision

Rowan Receives Landmark Gift to Fund Medical School Scholarships

To: EDUCATION AND HEALTH EDITORS

GLASSBORO, N.J., March 12, 2012 /PRNewswire-USNewswire/ -- To the core, Lawrence J. Salva is a numbers guy.

So when Salva, senior vice president, chief accounting officer and controller of Comcast Corporation, heard that the average medical school student graduates with more than $150,000 worth of debt, the Rowan University alumnus decided to make a difference and assist aspiring South Jersey physicians.

Salva, vice chairman of the Rowan University Foundation Board, and his wife, Rita, of Princeton, have pledged $1.055 million to the Foundation to establish the Lawrence & Rita Salva Medical Scholars Fund at Rowan. The single largest gift to date for Cooper Medical School of Rowan University (CMSRU), the Salvas' pledge also is the largest one-time gift ever made to Rowan by an alumnus.

Their gift will establish a $1 million endowment to benefit students enrolled at CMSRU. The additional $55,000 in contributions--and the

"The debt numbers for medical school students are just so compelling," says Salva, who earned his bachelor's degree in business from the University in 1977.

"We're absolutely excited about the medical school and the promise it holds for South Jersey. This scholarship fund gives us a tremendous opportunity to help medical school students pursue their dreams as they work to make a positive impact on the lives of others."

Supporting promising new physicians

According to Founding Dean Paul Katz, MD, tuition for a CMSRU student is $32,860 in state, $52,680 out-of-state. Including tuition, fees and living expenses, the average yearly cost of living for a medical school student in New Jersey is $57,400, according to Katz.

Medical school students often base their medical school decisions--and their choice of specialty--on their expected debt and the funding they can receive to help alleviate that debt. In the selection of the charter class, CMSRU has focused its mission to provide humanistic education in the art and science of medicine within a scientific and scholarly community in which inclusivity, excellence in patient care, innovative teaching, research, and service to the community are valued.

View post:
Rowan Receives Landmark Gift to Fund Medical School Scholarships

Cooper Medical School of Rowan University receives $1.055 million gift from senior vice president of Comcast Corporation

GLASSBORO On Monday, Cooper Medical School of Rowan University received its largest gift yet a $1.055 million endowment to the Rowan University Foundation for medical student scholarships.

Lawrence J. Salva senior vice president, chief accounting officer and controller of Comcast Corporation and his wife, Rita, of Princeton, have pledged this amount to establish the Lawrence & Rita Salva Medical Scholars Fund at Rowan.

The gift will establish a $1 million endowment to benefit students enrolled at CMSRU for years to come. The additional $55,000, and the earnings on the endowment, will provide $100,000 in scholarships for the medical schools charter class. The Camden school will welcome its first class this August.

Today is truly a great day for Rowan, the medical school and South Jersey, said R.J. Tallarida, assistant vice president for development and acting executive director of the Rowan University Foundation. Larry is a 1977 graduate, and this is the largest one-time gift by a Rowan alum the Foundation has ever received.

Rowan Interim President Ali Houshmand called the gift transformative.

Every time this scholarship helps to train a doctor who goes on to treat many ill people, the legacy of the endowment continues, said Houshmand. This will benefit many for years to come, especially in a time when student debt is such a serious issue in the country.

CMSRU Founding Dean Dr. Paul Katz said medical students face an enormous amount of debt. The average medical student graduates with nearly $150,000 worth of debt, and he said about 30 percent of the students accepted at CMSRU will be considered disadvantaged. The tuition for a CMSRU student will be approximately $32,860 in-state and $52,680 for out-of-state students. According to Katz, the average annual cost of living for a medical school student in New Jersey is $57,400.

What kind of impact does this have on career choice? said Katz. This is why positions in primary care come up short. In 2020, there are predicted to be 40,000 fewer primary care physicians in this area than are needed.

Add to that, said Katz, that most students come to medical school already bearing debt from their undergraduate years.

The impact of this gift is a multiplier, said Katz. Every patient they touch will benefit from this generosity.

Read the rest here:
Cooper Medical School of Rowan University receives $1.055 million gift from senior vice president of Comcast Corporation

How Important Are Medical School Rankings?

Medical school rankings are one indicator of an institution's perceived quality; however, gauging the importance of rankings is not as clear-cut as with undergraduate institutions, law schools, and business schools.

With law schools and business schools, there is a wealth of data suggesting that the employment rate as well as the initial salary and bonus post-graduation gets higher the closer you get to the top of the rankings. This incentivizes students to attend the highest-ranked school possible.

In contrast, all medical school graduates who choose to go directly into a residency training program (which is required if you want to practice clinical medicine) make roughly the same amount of money during their training program. The income differential arises post-residency and is dependent upon the choice of specialty.

That said, attending certain medical schools can increase the chance of matching in your desired specialty choice, and the medical research rankings are arguably more important if you are an aspiring M.D./Ph.D. candidate. But your future opportunities will be more tightly coupled with your performance during medical school and your United States Medical Licensing Examination (USMLE) scores than the name of the institution on your degree.

[Learn more about joint M.D./Ph.D. programs.]

So how big of an influence should rankings be on school selection?

Unfortunately, not everybody can go to Harvard Medical School or University of Pennsylvania. However, there are more than 100 medical schools in the United States, as well as numerous overseas, that students enthusiastic about a career in medicine can consider.

When applying to medical school, the influence of rankings on what schools to apply to should depend on your objectives. For an aspiring physician scientist, being at a top-ranked research school that has the resources, aggressive publishing expectations, postdoctoral fellows, and grant-writing expertise can enhance your academic opportunities and set you up for future success.

For the aspiring clinician, rankings should be factored in, but can play second fiddle to the geographic, demographic, average MCAT score/average GPA, and academic culture of the institution.

[Find out what looming MCAT changes will mean for aspiring M.D.'s.]

See the original post here:
How Important Are Medical School Rankings?

Cooper-Rowan medical school receives $1.055 million donation

Posted: Monday, March 12, 2012 2:30 pm | Updated: 7:05 pm, Mon Mar 12, 2012.

GLASSBOROSouth Jersey's new medical school has received a significant boost from a local couple.

Former Moorestown resident Lawrence Salva and his wife, Rita, donated $1.055 million to the Cooper Medical School at Rowan University in Camden.

Announced Monday, the gift is the largest donation ever received by the university from an alumnus. It also is the biggest gift to date earmarked for the medical school.

"The Salvas' gift truly is transformative and will have a lasting impact on Rowan University, our new medical school and the entire region," said R.J. Tallarida, assistant vice president for development.

The donation will establish a $1 million endowment to benefit medical school students. Earnings on the endowment, plus the additional $55,000 gift, are expected to provide $100,000 in scholarships for the school's charter class. The first students will begin classes in August.

Annual tuition for the medical school is $32,860 for in-state residents and $52,680 for those from out of state, according to Paul Katz, the school's founding dean. Fees and living expenses boost in-state annual costs to about $57,400, Katz said. The average medical student graduates with more than $150,000debt.

Many medical students base their education and speciality decisions on their anticipated debt and the funding available to help pay their costs, Katz said. The Salvas' gift will better allow students to choose their careers based on medical interests that could include areas with significant shortages, he said.

The newly established Lawrence and Rita Salva Medical Scholars Fund is expected to provide one or more of three distinct four-year scholarships annually. They include the Southern New Jersey Scholarship for students with financial need who have attended a kindergarten-through-12th-grade school district in South Jersey; the Founder Scholarship for students in financial need who come from traditionally disadvantaged backgrounds; and the Service Scholarship, which will be awarded to students who have performed more than 200 hours of volunteer service before matriculation.

During a news conference at Rowan's Campbell Library in Glassboro, Salva talked about his opportunities on campus and expressed a desire to help medical students get their career starts.

Read the original post:
Cooper-Rowan medical school receives $1.055 million donation

Red Meat a Ticket to Early Grave, Harvard Says

Just in time to spoil the promise of warm-weather picnics, Harvard scientists have found that daily consumption of red meat particularly the kind you might like to grill may significantly increase your risk of premature death.

While this much has long been suspected, perhaps even by you, the Harvard-led study is the first nuanced analysis to calculate the risk that a serving of red meat can have on your longevity compared with other protein sources.

The study measures, for example, how much one could expect to lower their risk of early death by replacing pork and beef with poultry, fish, nuts or beans can lower the risk of early death; they found chicken was at least as healthy an alternative to red meat as beans and whole grains.

"This paper does not give a green light to a low-fat, high-carb diet," senior author Frank Hu of Harvard School of Public Health (HSPH) told LiveScience. "Instead, it underscores the importance of types or quality of protein." [7 Foods Your Heart Will Hate]

The study was published today (March 12) online in the journal Archives of Internal Medicine.

120,000 people can't be wrong

The researchers, led by An Pan at HSPH, tapped into two longitudinal health studies the Health Professionals Follow-Up Study, and the Nurses' Health Study which capture health and dietary information from approximately 120,000 adults who were free of cardiovascular disease and cancer at the onset of the study and followed for up to 28 years.

For these subjects, 20 percent of whom died during the study, one daily serving of unprocessed red meat such as steak or pork chops was associated with a 13 percent increased risk of dying during the study. One daily serving of processed red meat, such as a hot dog or bacon, was associated with a 20 percent increased risk.

Conversely, replacing one serving of red meat with one serving of a healthy protein source was associated with a lower mortality risk: 19 percent lower when the meat was replaced with nuts; 14 percent for poultry; 14 percent for whole grains; 10 percent for legumes; 10 percent for low-fat dairy products; and 7 percent for fish. [Top 10 Leading Causes of Death]

"This study provides clear evidence that regular consumption of red meat, especially processed meat, contributes substantially to premature death," said Hu.

Go here to see the original:
Red Meat a Ticket to Early Grave, Harvard Says

How Engineering the Human Body Could Combat Climate Change

Some of the proposed modifications are simple and noninvasive. For instance, many people wish to give up meat for ecological reasons, but lack the willpower to do so on their own. The paper suggests that such individuals could take a pill that would trigger mild nausea upon the ingestion of meat, which would then lead to a lasting aversion to meat-eating. Other techniques are bound to be more controversial. For instance, the paper suggests that parents could make use of genetic engineering or hormone therapy in order to birth smaller, less resource-intensive children.

The lead author of the paper, S. Matthew Liao, is a professor of philosophy and bioethics at New York University. Liao is keen to point out that the paper is not meant to advocate for any particular human modifications, or even human engineering generally; rather, it is only meant to introduce human engineering as one possible, partial solution to climate change. He also emphasized the voluntary nature of the proposed modifications. Neither Liao or his co-authors, Anders Sandberg and Rebecca Roache of Oxford, approve of any coercive human engineering; they favor modifications borne of individual choices, not technocratic mandates. What follows is my conversation with Liao about why he thinks human engineering could be the most ethical and effective solution to global climate change.

Judging from your paper, you seem skeptical about current efforts to mitigate climate change, including market based solutions like carbon pricing or even more radical solutions like geoengineering. Why is that?

Liao: It's not that I don't think that some of those solutions could succeed under the right conditions; it's more that I think that they might turn out to be inadequate, or in some cases too risky. Take market solutions---so far it seems like it's pretty difficult to orchestrate workable international agreements to affect international emissions trading. The Kyoto Protocol, for instance, has not produced demonstrable reductions in global emissions, and in any event demand for petrol and for electricity seems to be pretty inelastic. And so it's questionable whether carbon taxation alone can deliver the kind of reduction that we need to really take on climate change.

With respect to geoengineering, the worry is that it's just too risky---many of the technologies involved have never been attempted on such a large scale, and so you have to worry that by implementing these techniques we could endanger ourselves or future generations. For example it's been suggested that we could alter the reflectivity of the atmosphere using sulfate aerosol so as to turn away a portion of the sun's heat, but it could be that doing so would destroy the ozone layer, which would obviously be problematic. Others have argued that we ought to fertilize the ocean with iron, because doing so might encourage a massive bloom of carbon-sucking plankton. But doing so could potentially render the ocean inhospitable to fish, which would obviously also be quite problematic.

One human engineering strategy you mention is a kind of pharmacologically induced meat intolerance. You suggest that humans could be given meat alongside a medication that triggers extreme nausea, which would then cause a long-lasting aversion to meat eating. Why is it that you expect this could have such a dramatic impact on climate change?

Liao: There is a widely cited U.N. Food and Agricultural Organization report that estimates that 18% of the world's greenhouse gas emissions and CO2 equivalents come from livestock farming, which is actually a much higher share than from transportation. More recently it's been suggested that livestock farming accounts for as much as 51% of the world's greenhouse gas emissions. And then there are estimates that as much as 9% of human emissions occur as a result of deforestation for the expansion of pastures for livestock. And that doesn't even to take into account the emissions that arise from manure, or from the livestock directly. Since a large portion of these cows and other grazing animals are raised for consumption, it seems obvious that reducing the consumption of these meats could have considerable environmental benefits.

Even a minor 21% to 24% reduction in the consumption of these kinds of meats could result in the same reduction in emissions as the total localization of food production, which would mean reducing "food miles" to zero. And, I think it's important to note that it wouldn't necessarily need to be a pill. We have also toyed around with the idea of a patch that might stimulate the immune system to reject common bovine proteins, which could lead to a similar kind of lasting aversion to meat products.

Your paper also discusses the use of human engineering to make humans smaller. Why would this be a powerful technique in the fight against climate change?

Liao: Well one of the things that we noticed is that human ecological footprints are partly correlated with size. Each kilogram of body mass requires a certain amount of food and nutrients and so, other things being equal, the larger person is the more food and energy they are going to soak up over the course of a lifetime. There are also other, less obvious ways in which larger people consume more energy than smaller people---for example a car uses more fuel per mile to carry a heavier person, more fabric is needed to clothe larger people, and heavier people wear out shoes, carpets and furniture at a quicker rate than lighter people, and so on.

Read the original post:
How Engineering the Human Body Could Combat Climate Change

How Human Engineering Could Be the Solution to Climate Change

Some of the proposed modifications are simple and noninvasive. For instance, many people wish to give up meat for ecological reasons, but lack the willpower to do so on their own. The paper suggests that such individuals could take a pill that would trigger mild nausea upon the ingestion of meat, which would then lead to a lasting aversion to meat-eating. Other techniques are bound to be more controversial. For instance, the paper suggests that parents could make use of genetic engineering or hormone therapy in order to birth smaller, less resource-intensive children.

The lead author of the paper, S. Matthew Liao, is a professor of philosophy and bioethics at New York University. Liao is keen to point out that the paper is not meant to advocate for any particular human modifications, or even human engineering generally; rather, it is only meant to introduce human engineering as one possible, partial solution to climate change. He also emphasized the voluntary nature of the proposed modifications. Neither Liao or his co-authors, Anders Sandberg and Rebecca Roache of Oxford, approve of any coercive human engineering; they favor modifications borne of individual choices, not technocratic mandates. What follows is my conversation with Liao about why he thinks human engineering could be the most ethical and effective solution to global climate change.

Judging from your paper, you seem skeptical about current efforts to mitigate climate change, including market based solutions like carbon pricing or even more radical solutions like geoengineering. Why is that?

Liao: It's not that I don't think that some of those solutions could succeed under the right conditions; it's more that I think that they might turn out to be inadequate, or in some cases too risky. Take market solutions---so far it seems like it's pretty difficult to orchestrate workable international agreements to affect international emissions trading. The Kyoto Protocol, for instance, has not produced demonstrable reductions in global emissions, and in any event demand for petrol and for electricity seems to be pretty inelastic. And so it's questionable whether carbon taxation alone can deliver the kind of reduction that we need to really take on climate change.

With respect to geoengineering, the worry is that it's just too risky---many of the technologies involved have never been attempted on such a large scale, and so you have to worry that by implementing these techniques we could endanger ourselves or future generations. For example it's been suggested that we could alter the reflectivity of the atmosphere using sulfate aerosol so as to turn away a portion of the sun's heat, but it could be that doing so would destroy the ozone layer, which would obviously be problematic. Others have argued that we ought to fertilize the ocean with iron, because doing so might encourage a massive bloom of carbon-sucking plankton. But doing so could potentially render the ocean inhospitable to fish, which would obviously also be quite problematic.

One human engineering strategy you mention is a kind of pharmacologically induced meat intolerance. You suggest that humans could be given meat alongside a medication that triggers extreme nausea, which would then cause a long-lasting aversion to meat eating. Why is it that you expect this could have such a dramatic impact on climate change?

Liao: There is a widely cited U.N. Food and Agricultural Organization report that estimates that 18% of the world's greenhouse gas emissions and CO2 equivalents come from livestock farming, which is actually a much higher share than from transportation. More recently it's been suggested that livestock farming accounts for as much as 51% of the world's greenhouse gas emissions. And then there are estimates that as much as 9% of human emissions occur as a result of deforestation for the expansion of pastures for livestock. And that doesn't even to take into account the emissions that arise from manure, or from the livestock directly. Since a large portion of these cows and other grazing animals are raised for consumption, it seems obvious that reducing the consumption of these meats could have considerable environmental benefits.

Even a minor 21% to 24% reduction in the consumption of these kinds of meats could result in the same reduction in emissions as the total localization of food production, which would mean reducing "food miles" to zero. And, I think it's important to note that it wouldn't necessarily need to be a pill. We have also toyed around with the idea of a patch that might stimulate the immune system to reject common bovine proteins, which could lead to a similar kind of lasting aversion to meat products.

Your paper also discusses the use of human engineering to make humans smaller. Why would this be a powerful technique in the fight against climate change?

Liao: Well one of the things that we noticed is that human ecological footprints are partly correlated with size. Each kilogram of body mass requires a certain amount of food and nutrients and so, other things being equal, the larger person is the more food and energy they are going to soak up over the course of a lifetime. There are also other, less obvious ways in which larger people consume more energy than smaller people---for example a car uses more fuel per mile to carry a heavier person, more fabric is needed to clothe larger people, and heavier people wear out shoes, carpets and furniture at a quicker rate than lighter people, and so on.

Visit link:
How Human Engineering Could Be the Solution to Climate Change

Nobel-winning UCI chemistry professor Sherry Rowland remembered

The world's largest natural products convention, a celebration of all things healthy and eco-friendly, was being held at the Anaheim Convention Center Saturday when F. Sherwood Rowland, 84, died at his home in Corona del Mar.

It's not much of a stretch to say that Rowland, 84, helped spawn the industry that drew more than 60,000 people and 2,000 exhibitors. In 1973, the UC Irvine chemistry professor and a young researcher on his team, Mario Molina, discovered that manmade chemicals called chlorofluorocarbons destroyed the Earth's fragile and vital ozone layer.

The pair faced criticism and scorn from the chemical industry before being vindicated and winning the Nobel Prize for chemistry in 1995. In 1987, the international Montreal Treaty was ratified to phase out CFCs, which were found in aerosol sprays, electronic solvents and air-conditioning coolants.

As I walked the convention floor this weekend, I saw entrepreneurs with products that aim to respect human health and the Earth's precious resources. I don't think Sherry Rowland, a plain-spoken and no-nonsense kind of guy, would wax enthusiastic over acai berry-green tea energy drinks, chia-seed cranberry bars or compostable baby diapers. But I think he would appreciate the idea that people need to be careful with what they do to their bodies and the planet. He called it "being prudent."

I wrote a book about Rowland and Molina's discovery in 1988 (The Ozone Crisis). At first I was intimidated by Rowland when I sought him out to write the book. He was twice my size (6 feet, 5 inches), twice my age and had at least twice my IQ. I was pregnant and sick that year, but he was kind and patient, submitting to many interviews and turning over reams of books and notes to me.

He showed the same generosity to his students teaching undergraduate chemistry at UC Irvine for many years and hanging out in the lab with grad students and colleagues until just a few months ago. He didn't reap huge financial gain from his research. He was just a scientist with a deep sense of humanity. Orange County, UC Irvine the world was lucky to have him.

Follow me: twitter.com/LATShariRoan

See the rest here:
Nobel-winning UCI chemistry professor Sherry Rowland remembered

NMBio Announces Scholarship Award

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--

The New Mexico Biotechnology and Biomedical Association (NMBio) has announced a new scholarship award to be presented to a New Mexico high school senior graduating in the spring of 2012. The $1,000 award will be presented to a student meeting the following criteria: 1) be accepted to a two- or four-year accredited New Mexico college, and 2) plan to major in an area that will lead to a career in a biotechnology or biomedical field. The decision to award the scholarship will be based on a one-page letter of intent in which the student describes their biomedical or biotechnology career goals. High school GPA, a letter of recommendation and college entrance exam scores will also be considered. Documentation of acceptance to a school, the letter of intent, an official copy of the high school transcripts, a letter of recommendation, and SAT or ACT scores should be sent to: NMBioScholarship@gmail.com.

For more information on this scholarship, please check our listing on scholarships.com. Look for The New Mexico Biotechnology and Biomedical Association (NMBio) Scholarship. Scholarship information and an application are also available on our website at http://www.nmbio.org.

NMBio is pleased to invest in the future biotechnology and biomedical professionals in the state of New Mexico though our new scholarship program, said NMBio President Andrew Salazar. One of our primary aims is to foster the growth of the biosciences industry in the state, and this scholarship is one of the ways we will be assisting New Mexico high school students that plan to pursue a career in the biosciences during these challenging economic times.

NMBio Board member Charlotte Mobarak added, We are thrilled to be able to offer this scholarship in addition to our sponsorship of local science fairs and the other educational initiatives of NMBio. We look forward to receiving applications and forming relationships with the future biosciences professionals in the state.

About The New Mexico Biotechnology and Biomedical Association:

The New Mexico Biotechnology and Biomedical Association (NMBio) actively supports and promotes the development of the biosciences industry in the state. The association provides a forum for information exchange, develops initiatives to enhance business success, offers education regarding bioscience in the state, helps establish collaboration, and serves as a voice of the industry to state, federal and local governments.

The rest is here:
NMBio Announces Scholarship Award

Homing in a life-saving treatment for shock

SAN DIEGO A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego, bioengineering professor Geert Schmid-Schnbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications and new-onset gastrointestinal bleeding.

This new use of a Food and Drug Administration-approved drug is based on decades of research by Schmid-Schnbein on the microvascular and cellular reactions that lead to multi-organ failure after a patient has gone into shock, which is the second-leading cause of in-hospital deaths in the United States.

Schmid-Schnbein and his colleagues at the UC San Diego Jacobs School of Engineering discovered that under conditions of shock, the epithelial cell barrier that lines the small intestine becomes permeable causing potent digestive enzymes to be carried into the bloodstream and lymphatic system where they digest and destroy healthy tissue, a process he named autodigestion. The treatment involves blockading the enzymes with an enzyme inhibitor.

In 2005, the teams protocol was licensed to San Diego-startup InflammaGen Therapeutics under an agreement developed by UC San Diegos Technology Transfer Office. InflammaGen Therapeutics, a development-stage, critical care company, developed the InflammaGen Shok-Pak, a drug/delivery platform that delivers the enzyme inhibitor through a nasogastric tube directly into the stomach and lumen of the intestine, preventing shock and multi-organ failure. Schmid-Schnbein serves as a scientific advisor to InflammaGen but is not an employee of the company. Instead, he has chosen to focus on continuing to conduct fundamental research on autodigestion at UC San Diego.

"We are testing for the first time whether it is possible to help severely ill patients by blocking autodigestion, a condition in which digestive enzymes not only break down food inside the intestine but also the intestine itself, Schmid-Schnbein said. We have pre-clinical results that this treatment can save lives.

To date, InflammaGen Shok-Pak has been used successfully outside the United States as a rescue therapy in 15 patients, most of whom were diagnosed with life-threatening conditions. In addition, pre-clinical studies of the technology in two animal species have demonstrated significant increases in long-term survival.

Currently, patients in shock who survive their initial insult dont necessarily survive long-term. In addition, morbidity is very high in those patients that do survive. Our animal studies suggest that the treatment could improve functional outcomes and reduce the time patients remain in intensive care, as well as increase long-term survival rates, said principal investigator Dr. Erik Kistler, who currently serves as an assistant clinical professor in the Department of Anesthesiology and Critical Care at the UC San Diego School of Medicine and the Veterans Administration Healthcare System, San Diego. While ICU costs can approach one-third of the entire hospital costs, decreasing ICU time by even a small percentage a day will have significant financial savings for patients and payors as well as result in significantly improved patient wellness, said Kistler, who earned a doctorate (1998) and masters (1994) in bioengineering from the Jacobs School of Engineering as a student of Schmid-Schnbeins.

The Phase 2 pilot is designed as a double-blind, standard-therapy controlled study of 200 critically ill ICU patients. The goal is to determine the safety and efficacy of the gastrointestinal administration of InflammaGen Shok-Pak in the reduction of morbidity, which is defined as the incidence of disease. The team wants to know whether the treatment will reduce the time patients spend in intensive care and the hospital, and improve long-term survival rates. To determine this, researchers will follow up with patients 28 days and six months after discharge. The Phase 2 pilot study will be conducted at the Intensive Care Unit (ICU) at the VA San Diego Healthcare System, with additional sites being added as appropriate.

John Rodenrys, CEO of InflammaGen Therapeutics, remarked, Initiation of the Phase 2 pilot study is a key milestone in the development of InflammaGen Shok-Pak as a potential treatment for sepsis and septic shock, which may result in multi-organ failure, a highly-invasive condition for which there is currently no effective therapy option.

Hank Loy, president of InflammaGen Therapeutics, added, We look forward to working with the investigative team at the VA San Diego Healthcare System and expect their experiences to demonstrate the benefits of InflammaGen Shok-Pak, which have been evident in the pre-clinical studies and ex-U.S. patient experiences.

Read more here:
Homing in a life-saving treatment for shock

Solving Climate Change By Bioengineering Humans?

Join Log In Submit Story Jobs Newsletter Library 30334639 story Posted by Soulskill on Monday March 12, @05:13PM from the just-lazy-enough-to-work dept. derekmead writes "Forget CFLs, hybrid cars, and organic jeans. Buying our way out of climate change even if it's green consumption won't get us far. A new paper (PDF), published in Ethics, Policy, and the Environment by NYU bioethics professor S. Matthew Liao, poses an answer: engineer humans to use less. The general plan laid out by Liao is straightforward, ranging from using pharmacological behavior modification to create an aversion to meat in people, to using gene therapy to create smaller, less resource-intensive children. The philosophical and ethical questions, on the other hand, are absurdly complicated. The Atlantic also has a great interview with Liao, in which he talks about gene therapy and making humans hate the taste of meat." You may like to read: Post

love, n.: When it's growing, you don't mind watering it with a few tears.

Working...

Go here to read the rest:
Solving Climate Change By Bioengineering Humans?

Repairing mutations in human mitochondria

LOS ANGELES Researchers at the UCLA stem cell center and the departments of chemistry and biochemistry and pathology and laboratory medicine have identified, for the first time, a generic way to correct mutations in human mitochondrial DNA by targeting corrective RNAs, a finding with implications for treating a host of mitochondrial diseases.

Mutations in the human mitochondrial genome are implicated in neuromuscular diseases, metabolic defects and aging. There currently are no methods to successfully repair or compensate for these mutations, said study co-senior author Dr. Michael Teitell, a professor of pathology and laboratory medicine and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

Between 1,000 and 4,000 children per year in the United States are born with a mitochondrial disease and up to one in 4,000 children in the U.S. will develop a mitochondrial disease by the age of 10, according to Mito Action, a nonprofit organization supporting research into mitochondrial diseases. In adults, many diseases of aging have been associated with defects of mitochondrial function, including diabetes, Parkinson's disease, heart disease, stroke, Alzheimer's disease and cancer.

"I think this is a finding that could change the field," Teitell said. "We've been looking to do this for a long time and we had a very reasoned approach, but some key steps were missing. Now we have developed this method and the next step is to show that what we can do in human cell lines with mutant mitochondria can translate into animal models and, ultimately, into humans."

The study appears today in the peer-reviewed journal Proceedings of the National Academy of Sciences.

The current study builds on previous work published in 2010 in the peer-reviewed journal Cell, in which Teitell, Carla Koehler, a professor of chemistry and biochemistry and a Broad stem cell research center scientist, and their team uncovered a role for an essential protein that acts to shuttle RNA into the mitochondria, the energy-producing "power plant" of a cell.

Mitochondria are described as cellular power plants because they generate most of the energy supply within a cell. In addition to supplying energy, mitochondria also are involved in a broad range of other cellular processes including signaling, differentiation, death, control of the cell cycle and growth.

The import of nucleus-encoded small RNAs into mitochondria is essential for the replication, transcription and translation of the mitochondrial genome, but the mechanisms that deliver RNA into mitochondria have remained poorly understood.

The study in Cell outlined a new role for a protein called polynucleotide phosphorylase (PNPASE) in regulating the import of RNA into mitochondria. Reducing the expression or output of PNPASE decreased RNA import, which impaired the processing of mitochondrial genome-encoded RNAs. Reduced RNA processing inhibited the translation of proteins required to maintain the mitochondrial electron transport chain that consumes oxygen during cell respiration to produce energy. With reduced PNPASE, unprocessed mitochondrial-encoded RNAs accumulated, protein translation was inhibited and energy production was compromised, leading to stalled cell growth.

The findings from the current study provide a form of gene therapy for mitochondria by compensating for mutations that cause a wide range of diseases, said study co-senior author Koehler.

Read the original:
Repairing mutations in human mitochondria

Correcting human mitochondrial mutations

Public release date: 12-Mar-2012 [ | E-mail | Share ]

Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Health Sciences

Researchers at the UCLA stem cell center and the departments of chemistry and biochemistry and pathology and laboratory medicine have identified, for the first time, a generic way to correct mutations in human mitochondrial DNA by targeting corrective RNAs, a finding with implications for treating a host of mitochondrial diseases.

Mutations in the human mitochondrial genome are implicated in neuromuscular diseases, metabolic defects and aging. There currently are no methods to successfully repair or compensate for these mutations, said study co-senior author Dr. Michael Teitell, a professor of pathology and laboratory medicine and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

Between 1,000 and 4,000 children per year in the United States are born with a mitochondrial disease and up to one in 4,000 children in the U.S. will develop a mitochondrial disease by the age of 10, according to Mito Action, a nonprofit organization supporting research into mitochondrial diseases. In adults, many diseases of aging have been associated with defects of mitochondrial function, including diabetes, Parkinson's disease, heart disease, stroke, Alzheimer's disease and cancer.

"I think this is a finding that could change the field," Teitell said. "We've been looking to do this for a long time and we had a very reasoned approach, but some key steps were missing. Now we have developed this method and the next step is to show that what we can do in human cell lines with mutant mitochondria can translate into animal models and, ultimately, into humans."

The study appears March 12, 2012 in the peer-reviewed journal Proceedings of the National Academy of Sciences.

The current study builds on previous work published in 2010 in the peer-reviewed journal Cell, in which Teitell, Carla Koehler, a professor of chemistry and biochemistry and a Broad Stem Cell Research Center scientist, and their team uncovered a role for an essential protein that acts to shuttle RNA into the mitochondria, the energy-producing "power plant" of a cell.

Mitochondria are described as cellular power plants because they generate most of the energy supply within a cell. In addition to supplying energy, mitochondria also are involved in a broad range of other cellular processes including signaling, differentiation, death, control of the cell cycle and growth.

The import of nucleus-encoded small RNAs into mitochondria is essential for the replication, transcription and translation of the mitochondrial genome, but the mechanisms that deliver RNA into mitochondria have remained poorly understood.

Go here to see the original:
Correcting human mitochondrial mutations

OriGene Technologies Announces the Acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd, a Leading …

ROCKVILLE, Md., March 12, 2012 /PRNewswire/ --OriGene Technologies, Inc. announces the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). The strategic acquisition establishes OriGene's leading position in the Chinese pathology testing market.

Headquartered in Beijing, China since 1993, ZsBio provides pathology testing products to the growing Chinese oncology diagnostic market. ZsBio has an industry leading position in the Chinese pathology testing market because of its innovative product portfolio, expertise, strong client relationships, and has established itself as a thought leader in the Chinese pathology diagnostic field. The Chinese pathology testing market has been experiencing double-digit growth annually and is one of the fast-growing segments of the Chinese diagnostic industry.

"With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene," commented Wei-Wu He, CEO of OriGene. "ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative highly specific monoclonal antibodies and assays to complement and strengthen ZsBio's portfolio of products."

About OriGene Technologies

About Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd

Read the original here:
OriGene Technologies Announces the Acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd, a Leading ...

New Cross pathology centre frame in place

A new 9 million pathology centre at New Cross Hospital in Wolverhampton is beginning to take shape with the steel frame now in place.

The three-storey centre will house microbiology, haematology, clinical chemistry and hist-opathology units. Work began on the facility in September. It is due to be finished later this year and open in early 2013.

With the steel frame now in place, concrete floors are being installed on all three floors.

David Loughton, chief executive of Royal Wolverhampton Hospitals NHS Trust, said: Its great to see this project taking shape on a daily basis. This is going to be a really important facility and is another significant project in our redevelopment of the New Cross site.

The 4,160sqm facility will include a number of new laboratories and facilities.

The work is being carried out by construction and infrastructure company Morgan Sindall.

Bosses at New Cross Hospital say the facility will cut waiting times for thousands of patients.

The pathology department will increase the speed test results are returned, meaning pat-ients can be treated faster and leave hospital quicker. The pathology department handles more than 1.2 million requests for work. It includes blood tests, urine tests, and identifying viral and bacterial infections among patients.

It is also hoped the lab will eliminate delays and reduce handling of samples which will lead to an overall improvement in the quality of the patient experience in hospital.

The four existing buildings house the departments of microbiology, blood sciences, clinical chemistry, histopathology and cytology. But they are old and ineffective.

Read more here:
New Cross pathology centre frame in place

Innovation Sparks Success – Nutracon and Engredea Post Record Numbers

BOULDER, Colo., March 12, 2012 /PRNewswire/ --Nutracon and Engredea, two focused ingredient and supply chain events in the U.S. nutrition industry, posted record attendance last week at the Anaheim Convention Center.Nutracon and Engredea, co-located with Natural Products Expo West, are events devoted to innovation and next-generation product development across the healthy food, beverage, dietary supplement, bioactive and NutriCosmetic markets. Nutracon and Engredea drew over 220 exhibitors and 7,500 buyers and influencers over five days.

"The global healthy products market is booming, and so are the ingredients and innovation that fuel it," noted Len Monheit, Executive Director of Engredea and Nutrition Business Journal."Early estimates indicate 8% nutrition industry growth and 6.5% supplement industry growth in 2011.To keep pace we've made great investments this year including a large hosted VIP program, the Innovodex mobile app, the Innovation Station and a new focus on international business development via the Market QuickStart program in India and China. These investments are what define Nutracon and Engredea today, but this is just the start we plan to build on these exciting programs for many years to come."

"I get more work done in three days here than three weeks in the office," said Gabe Herrick, Director of Sales for Bioenergy Life Science. "We continue to meet the right contacts and leads that spur innovation and I can't wait to start following up."

Innovation, a theme at the show, took center stage at Nutracon as Zychrome from InterHealth Nutraceuticals and Portobello Mushroom Powder from Dole Nutrition Institute took home the 2012 NutrAward for Best New Ingredient and Best New Finished Product, respectively.

2012 also marked the launch of New Hope Natural Media's Hall of Legends, an awards ceremony recognizing those individuals who have made considerable contributions to the success of the natural products industry.

In addition, Functional Ingredients magazine editors combed the Engredea show floor to identify and honor the most innovative exhibitors with Editors' Choice Awards. The 2012 Editors' Choice Award winners include:

2012 Best Science: Helios Corp

2012 Best Marketing: Sabinsa, Curcumin C3 Complex

2012 Best Partnership: DSM and Provexis

2012 Best Botanical: Ilhwa Co., Gin ST15

Read the rest here:
Innovation Sparks Success - Nutracon and Engredea Post Record Numbers